Semaglutide Research for Sleep Apnea
An evidence-based overview of research examining Semaglutide in the context of sleep apnea. This page synthesizes findings from peer-reviewed literature.
Research Summary
While not specifically FDA-approved for sleep apnea, semaglutide's substantial weight loss effects may benefit obstructive sleep apnea (OSA), which is strongly associated with obesity. Weight loss is a primary treatment recommendation for OSA. Tirzepatide, a related GLP-1/GIP dual agonist, received FDA approval for moderate-to-severe OSA in adults with obesity (December 2024), but this other drug's result and weight loss in semaglutide obesity trials cannot establish semaglutide efficacy for OSA. Dedicated clinical trials of semaglutide for sleep apnea would be needed to establish direct efficacy in this indication.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.